Diligence memo · auto-generated · as of July 2, 2026
Veana Therapeutics, Inc.
Veana Therapeutics, Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Veana Therapeutics, Inc. operates in Pharmaceuticals, based in PORTLAND.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Veana Therapeutics, Inc. has raised $1.4M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $831K on 2020-10-21.
Most recent recorded round closed around 2020-10-21.
Valuation (modeled)modeled
Provath models Veana Therapeutics, Inc. at approximately $33M (range $465K–$340M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.46× the median modeled value of Pre-Seed Pharmaceuticals companies in 2019–2021 (46 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 29 months.
Last raise 5.7 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 1.5× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 23% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 35% of those peers.
Closest niche peers: Elion Oncology, Inc., Cyclone Therapeutics, Inc., Sonnet Biotherapeutics, Inc., Fastball Capital Group, Llc, TamRx, LLC.
Peoplefiled
12 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.